Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
May 17, 2024 17:15 ET
|
Iovance Biotherapeutics, Inc.
SAN CARLOS, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and...
Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
May 17, 2024 17:00 ET
|
Achilles Therapeutics PLC
LONDON, May 17, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal...
Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action
May 17, 2024 17:00 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., May 17, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Plus Therapeutics Announces New Employment Inducement Grants
May 17, 2024 17:00 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Announces New Employment Inducement Grants
BriaCell Therapeutics Announces Closing of $5.0 Million Registered Direct Offering
May 17, 2024 16:33 ET
|
BriaCell Therapeutics Corp.
PHILADELPHIA and VANCOUVER, British Columbia, May 17, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage...
DBV Technologies annonce son intention de modifier le ratio d'ADS
May 17, 2024 16:30 ET
|
DBV Technologies S.A.
Châtillon, France, le 17 mai 2024 DBV Technologies annonce son intention de modifier le ratio d'ADS DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT—CUSIP:...
Oculis updates share capital for its existing at-the-market offering program
May 17, 2024 16:30 ET
|
Oculis Holding AG
ZUG, May 17, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company, has issued registered ordinary shares of the...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 17, 2024 16:30 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Nuvini (Nasdaq: NVNI) Announces Nasdaq Notification of Non-Compliance Regarding Delayed Form 20-F Filing
May 17, 2024 16:30 ET
|
Nvni Group Limited
Nvni Group Limited announced that it received a notice from Nasdaq indicating the Company's non-compliance with Nasdaq Listing Rule 5250(c)(1).
DZS Inc. Receives Expected Nasdaq Notice Regarding Late Form 10-Q Filing
May 17, 2024 16:30 ET
|
DZS
DZS Inc. Receives Expected Nasdaq Notice Regarding Late Form 10-Q Filing